MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery

MaxCyte Inc. (NASDAQ:MXCT) is one of the best penny stocks under $1 to buy right now. On February 24, MaxCyte launched the ExPERT DTx, which is a high-throughput 96-well electroporation platform designed to accelerate research and drug discovery. This modular system allows labs to transfect primary cells and various cell lines with minimal cellular stress, facilitating deep biological insights at the discovery stage.

By providing a reliable foundation for early-stage experiments, the platform enables researchers to transition seamlessly from initial discovery to larger transfection volumes without compromising cell health. The ExPERT DTx streamlines laboratory workflows by processing up to 96 samples in a single three-minute run. Its specialized R-50×96 assembly uses 12 detachable 8-well strips, allowing for parallel processing of different cell and cargo combinations with unique parameters.

Photo by Info MyCellHub on Unsplash

Furthermore, optimized processes can be transferred to other ExPERT instruments, simplifying the scale-up to cGMP-compliant manufacturing by eliminating the need for workflow re-optimization. To maximize laboratory efficiency, the platform features a specialized software suite that includes the DTx Designer. This tool allows researchers to design experiments remotely and upload them once the system is available, significantly increasing instrument uptime in busy, multi-user environments.

MaxCyte Inc. (NASDAQ:MXCT) is a life sciences company that discovers, develops, and commercializes cell therapeutics in the US and internationally.